Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis. Export

@article{citeulike:316774, abstract = {Patients with human immunodeficiency virus-1 (HIV) have elevated risk for hepatitis A virus (HAV) coinfection. Sequelae from coinfection include increased risk of liver-related morbidity and mortality. This study synthesizes the results of trials measuring response to HAV vaccine in HIV-infected patients using Bayesian meta-analysis methodologies. PubMed, OhioLINK/Medline, and other sources were used to search for studies analyzing response to HAV vaccine in HIV-infected patients. Studies were evaluated for quality. A Bayesian hierarchical random-effects model was used to estimate overall response to vaccine. Between-study variance was calculated. Sensitivity analyses were conducted to determine the potential for bias. The literature search yielded eight studies for inclusion in the meta-analysis, with a combined total of 458 patients. Observed proportions of response in individual studies ranged from 50 to 95\%. The intention-to-treat meta-analysis estimated a combined proportion of HIV+ patients responding to vaccine of 64\% (95\% CI 52-75\%). Heterogeneity between studies was significant. The overall response rate to HAV vaccine in HIV-infected patients is lower than typically cited. Up to 1/2 of HIV-infected patients may be nonresponders. Future research will be required to better understand the correlates of response.}, address = {College of Medicine, University of Cincinnati, 231 Albert Sabin Way, ML-0595, Cincinnati, OH 45267, USA.}, author = {Shire, Norah J J. and Welge, Jeffrey A A. and Sherman, Kenneth E E.}, citeulike-article-id = {316774}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.vaccine.2005.07.102}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/16139398}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=16139398}, day = {30}, doi = {10.1016/j.vaccine.2005.07.102}, issn = {0264-410X}, journal = {Vaccine}, keywords = {efficacy, hav, hiv, vaccine}, month = {August}, posted-at = {2005-09-13 14:02:18}, priority = {2}, title = {Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis.}, url = {http://dx.doi.org/10.1016/j.vaccine.2005.07.102}, year = {2005} }

TY - JOUR ID - citeulike:316774 L3 - citeulike-article-id:316774 N2 - Patients with human immunodeficiency virus-1 (HIV) have elevated risk for hepatitis A virus (HAV) coinfection. Sequelae from coinfection include increased risk of liver-related morbidity and mortality. This study synthesizes the results of trials measuring response to HAV vaccine in HIV-infected patients using Bayesian meta-analysis methodologies. PubMed, OhioLINK/Medline, and other sources were used to search for studies analyzing response to HAV vaccine in HIV-infected patients. Studies were evaluated for quality. A Bayesian hierarchical random-effects model was used to estimate overall response to vaccine. Between-study variance was calculated. Sensitivity analyses were conducted to determine the potential for bias. The literature search yielded eight studies for inclusion in the meta-analysis, with a combined total of 458 patients. Observed proportions of response in individual studies ranged from 50 to 95%. The intention-to-treat meta-analysis estimated a combined proportion of HIV+ patients responding to vaccine of 64% (95% CI 52-75%). Heterogeneity between studies was significant. The overall response rate to HAV vaccine in HIV-infected patients is lower than typically cited. Up to 1/2 of HIV-infected patients may be nonresponders. Future research will be required to better understand the correlates of response. JF - Vaccine SN - 0264-410X AD - College of Medicine, University of Cincinnati, 231 Albert Sabin Way, ML-0595, Cincinnati, OH 45267, USA. TI - Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis. KW - efficacy KW - hav KW - hiv KW - vaccine AU - Shire, Norah J AU - Welge, Jeffrey A AU - Sherman, Kenneth E PY - 2005/08/30/ UR - http://dx.doi.org/10.1016/j.vaccine.2005.07.102 ER -